{"ATC Code":"R - Respiratory system","Abbreviation":"","Aliases":["Travelin","Chloranautine","Diphenhydrinate","Vomex A","Anautine","Amosyt","Menhydrinate","Andramine","Diamarin","Dimenest"],"Biological Half-Life":"The plasma elimination half life of dimenhydrinate is 5-8 hours.","CAS":"523-87-5","ChEBI":"CHEBI:94848","ChEMBL":"CHEMBL1200406","ChemicalClasses":["xanthine"],"Chirality":"achiral","Classes":null,"Color/Form":"CRYSTALS","Drug Classes":"Breast Feeding; Lactation; Antihistamines; Antiemetics; Gastrointestinal Agents","Drug Indication":"Dimenhydrinate is indicated for the prevention and treatment of nausea, vomiting, or vertigo of motion sickness.","Drug Warnings":"SEE ANTIHISTAMINICS. CONSIDERABLE MARGIN OF SAFETY SEPARATES THERAPEUTIC DOSE FROM USUAL LETHAL ONE. HOWEVER, BECAUSE CONVULSANT DOSE LIES NEAR LETHAL DOSE, CONVULSIONS INDICATE POOR PROGNOSIS. ADULTS HAVE SURVIVED SINGLE DOSES OF 2.5-5.0 G. CHILDREN...30-60 MG/KG HAS PRODUCED...POISONINGS. /ANTIHISTAMINICS/","DrugClasses":[],"EINECS":"208-350-8","EliminationHalfLife":"5.5 hours\u003ca href='#cite_note-3'\u003e\u003csup\u003e[3]\u003c/sup\u003e\u003c/a\u003e (diphenhydramine component)","Erowid Experience Reports":[{"Author":"the Paperboy","Id":"10129","Title":"Where's My Bowling Ball?"},{"Author":"a_fan_of_naturals","Id":"102547","Title":"I Wish I Could've Done Something Else"},{"Author":"ImShady","Id":"103616","Title":"How Much Is Too Much"},{"Author":"psycho-active-ist","Id":"10410","Title":"Motion Sickness"},{"Author":"Lu","Id":"10785","Title":"Looking for a Spoon and a Bowl"},{"Author":"villager24","Id":"110599","Title":"Fighting Writer's Block"},{"Author":"Tom","Id":"11072","Title":"Real Dreams"},{"Author":"Treason","Id":"111095","Title":"The Most Terrifying Living Hell of My Life"},{"Author":"wagwangel","Id":"111556","Title":"I Enjoyed That Comfortable Fear"},{"Author":"Sean","Id":"111749","Title":"This Caused Damage"},{"Author":"Koda","Id":"11217","Title":"More Visuals Than I Could Shake a Stick At"},{"Author":"Fernando","Id":"112926","Title":"My Apartment Became the Devil's Playground"},{"Author":"Blaze","Id":"1135","Title":"Loss of All Reality"},{"Author":"Traxxus","Id":"11416","Title":"Pony"},{"Author":"Agent zoom","Id":"114699","Title":"A Fun Horror Trip"},{"Author":"Dimenhydrinate","Id":"11665","Title":"Chemical Addiction"},{"Author":"Chemlab","Id":"1201","Title":"Motion Sickness Delusions"},{"Author":"j-c-m-a-n","Id":"12424","Title":"Can't Breathe"},{"Author":"mary j","Id":"12466","Title":"I Can't Focus on the Words"},{"Author":"kman","Id":"12273","Title":"Don't Laugh at Me!"},{"Author":"Barry","Id":"14719","Title":"The Whole Day Just Seemed to Disappear"},{"Author":"Xyloform","Id":"15260","Title":"Fucked Up Pills: The Good \u0026 Bad"},{"Author":"BiGenderous","Id":"15277","Title":"Imaginary Friends"},{"Author":"Face","Id":"16062","Title":"A Fusing of the Concious and Subconcious"},{"Author":"Shay","Id":"16074","Title":"My New Dream World"},{"Author":"Roy","Id":"16552","Title":"Prognosis Negative"}],"European Community (EC) Number":"208-350-8","FDA Pharmacological Classification":"DIMENHYDRINATE","HeavyAtomCount":33,"Human Drugs":"Breast Feeding; Lactation; Antihistamines; Antiemetics; Gastrointestinal Agents","IUPACName":"2-benzhydryloxy-N,N-dimethylethanamine;8-chloro-1,3-dimethyl-7H-purine-2,6-dione","Impurities":["8-chlorocaffeine","theophylline anhydrous","nordiphenhydramine"],"InChI":"InChI=1S/C17H21NO.C7H7ClN4O2/c1-18(2)13-14-19-17(15-9-5-3-6-10-15)16-11-7-4-8-12-16;1-11-4-3(9-6(8)10-4)5(13)12(2)7(11)14/h3-12,17H,13-14H2,1-2H3;1-2H3,(H,9,10)","InChIKey":"NFLLKCVHYJRNRH-UHFFFAOYSA-N","MeSH Pharmacological Classification":"Drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine. Included here are the classical antihistaminics that antagonize or prevent the action of histamine mainly in immediate hypersensitivity. They act in the bronchi, capillaries, and some other smooth muscles, and are used to prevent or allay motion sickness, seasonal rhinitis, and allergic dermatitis and to induce somnolence. The effects of blocking central nervous system H1 receptors are not as well understood. (See all compounds classified as Histamine H1 Antagonists.)","Melting Point":"216 to 225 °F (NTP, 1992)","MolecularFormula":"C\u003csub\u003e24\u003c/sub\u003eH\u003csub\u003e28\u003c/sub\u003eClN\u003csub\u003e5\u003c/sub\u003eO\u003csub\u003e3\u003c/sub\u003e","MolecularWeight":"470.0 g/mol","Odor":"ODORLESS","Pharmacodynamics":"Dimenhydrinate is indicated for the prevention and treatment of nausea, vomiting, or vertigo of motion sickness. It has a short duration of action of 4-8 hours. Patients should be counselled regarding pronounced drowsiness, avoiding alcohol and other sedatives, and exercising caution when operating a motor vehicle or heavy machinery.","Physical Description":"Dimenhydrinate is a crystalline white powder. (NTP, 1992)","PrevSalts":[],"PubChemId":10660,"Record Description":["Dimenhydrinate is a crystalline white powder. (NTP, 1992)","8-chloro-1,3-dimethyl-7H-purine-2,6-dione 2-(diphenylmethyl)oxy-N,N-dimethylethanamine is a diarylmethane.","Dimehydrinate was first described in the literature in 1949, and patented in 1950. Early research into dimenhydrinate focused on its role as an antihistamine for urticaria; the treatment of motion sickness was an accidental discovery.  Dimenhydrinate, also known as B-dimethylaminoethyl benzohydrol ether 8-chlorotheophyllinate, is indicated to prevent nausea, vomiting, and dizziness caused by motion sickness. Dimenhydrinate is a combination of [Diphenhydramine] and [8-chlorotheophylline] in a salt form, with 53%-55.5% dried diphenhydramine, and 44%-47% died 8-chlorotheophylline.  The antiemetic properties of dimenhydrinate are primarily thought to be produced by diphenhydramine's antagonism of H1 histamine receptors in the vestibular system while the excitatory effects are thought to be produced by 8-chlorotheophylline's adenosine receptor blockade.  When used in large doses, dimenhydrinate has been shown to cause a \"high\" characterized by hallucinations, excitement, incoordination, and disorientation.  Dimenhydrinate was granted FDA approval on 31 May 1972.","Dimenhydrinate is a first generation antihistamine that is used for treatment or prevention of motion sickness or symptoms of nausea and dizziness. Dimenhydrinate has not been linked to instances of clinically apparent acute liver injury.","Dimenhydrinate is an ethanolamine and first-generation histamine antagonist with anti-allergic activity. Dimenhydrinate competitively blocks H1 receptors, thereby preventing the actions of histamine on bronchial smooth muscle, capillaries and gastrointestinal (GI) smooth muscle. This prevents histamine-induced bronchoconstriction, vasodilation, increased capillary permeability, GI smooth muscle spasm.","DIMENHYDRINATE is a small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1972 and is indicated for allergic disease and has 2 investigational indications.","A drug combination that contains diphenhydramine and theophylline. It is used for treating VERTIGO, MOTION SICKNESS, and NAUSEA associated with PREGNANCY.","See also: Diphenhydramine (has active moiety); 8-Chlorotheophylline (has active moiety).","8-chloro-1,3-dimethyl-7H-purine-2,6-dione 2-(diphenylmethyl)oxy-N,N-dimethylethanamine is a diarylmethane.","LiverTox|CNS|Sedative/Hypnotic|Antihistamine"],"RefCount":4,"References":[{"Name":"Wikipedia","Urls":[{"Link":"https://en.wikipedia.org/wiki/Dimenhydrinate","Name":"Dimenhydrinate","Sub":false}]},{"Name":"Wikidata","Urls":[{"Link":"https://www.wikidata.org/wiki/Q420439","Name":"Dimenhydrinate","Sub":false}]},{"Name":"DrugBank","Urls":[{"Link":"https://go.drugbank.com/drugs/DB00985","Name":"Dimenhydrinate","Sub":false}]},{"Name":"PubChem","Urls":[{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/10660","Name":"Dimenhydrinate","Sub":false}]},{"Name":"ChEMBL","Urls":[{"Link":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL1200406","Name":"Dimenhydrinate","Sub":false}]},{"Name":"ChEBI","Urls":[{"Link":"https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:94848","Name":"Dimenhydrinate","Sub":false}]},{"Name":"Common Chemistry","Urls":[{"Link":"https://commonchemistry.cas.org/detail?cas_rn=523-87-5","Name":"Dimenhydrinate","Sub":false}]},{"Name":"KEGG","Urls":[{"Link":"https://www.kegg.jp/entry/D00520","Name":"Dimenhydrinate","Sub":false}]},{"Name":"UNII","Urls":[{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/JB937PER5C","Name":"Dimenhydrinate","Sub":false}]},{"Name":"EPA DSSTox","Urls":[{"Link":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID9025087","Name":"Dimenhydrinate","Sub":false}]}],"Refs":["National Center for Biotechnology Information. PubChem Compound Summary for CID 10660, Dimenhydrinate. Accessed June 26, 2025. \u003ca href=https://pubchem.ncbi.nlm.nih.gov/compound/10660\u003ehttps://pubchem.ncbi.nlm.nih.gov/compound/10660\u003c/a\u003e","U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Dimenhydrinate. UNII: JB937PER5C. Global Substance Registration System. Accessed June 26, 2025. \u003ca href=https://gsrs.ncats.nih.gov/ginas/app/beta/substances/JB937PER5C\u003ehttps://gsrs.ncats.nih.gov/ginas/app/beta/substances/JB937PER5C\u003c/a\u003e","Scavone JM, Luna BG, Harmatz JS, von Moltke L, Greenblatt DJ. Diphenhydramine kinetics following intravenous, oral, and sublingual dimenhydrinate administration. Biopharmaceutics \u0026 Drug Disposition. April 1, 1990; 11(3):185–189."],"SMILES":"CN1C2=C(C(=O)N(C1=O)C)NC(=N2)Cl.CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2","Scheduling":[{"gov":"Australia","ref":[],"schedule":"S2 substance"},{"gov":"Canada","ref":[],"schedule":"Over-the-counter drug|OTC substance"},{"gov":"United States","ref":[],"schedule":"OTC substance"}],"Solubility":"Slightly soluble (1-10 mg/ml at 72 °F) (NTP, 1992)","StoreUNII":["JB937PER5C"],"StructureBase64":"<svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" height="101.136mm" version="1.2" viewBox="0 0 177.606 101.136" width="177.606mm">
      
    <desc>Generated by the Chemistry Development Kit (http://github.com/cdk)</desc>
      
    <g fill="#3050F8" stroke="#000000" stroke-linecap="round" stroke-linejoin="round" stroke-width=".7">
            
        <rect fill="#FFFFFF" height="102.0" stroke="none" width="178.0" x=".0" y=".0"/>
            
        <g class="mol" id="mol1">
                  
            <line class="bond" id="mol1bnd1" x1="121.877" x2="121.877" y1="81.048" y2="69.658"/>
                  
            <line class="bond" id="mol1bnd2" x1="125.031" x2="135.085" y1="63.989" y2="58.188"/>
                  
            <g class="bond" id="mol1bnd3">
                        
                <line x1="135.085" x2="135.085" y1="58.188" y2="42.948"/>
                        
                <line x1="132.647" x2="132.647" y1="56.78" y2="44.357"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd4" x1="135.085" x2="121.877" y1="42.948" y2="35.328"/>
                  
            <g class="bond" id="mol1bnd5">
                        
                <line x1="120.658" x2="120.658" y1="36.032" y2="24.009"/>
                        
                <line x1="123.097" x2="123.097" y1="36.032" y2="24.009"/>
                      
                <line class="hi" stroke="#FF0D0D" x1="120.658" x2="120.658" y1="24.009" y2="30.0205"/>
                <line class="hi" stroke="#FF0D0D" x1="123.097" x2="123.097" y1="24.009" y2="30.0205"/>
            </g>
                  
            <line class="bond" id="mol1bnd6" x1="121.877" x2="111.823" y1="35.328" y2="41.129"/>
                  
            <line class="bond" id="mol1bnd7" x1="108.669" x2="108.669" y1="46.798" y2="58.188"/>
                  
            <line class="bond" id="mol1bnd8" x1="118.724" x2="108.669" y1="63.989" y2="58.188"/>
                  
            <g class="bond" id="mol1bnd9">
                        
                <line x1="109.889" x2="99.36" y1="58.892" y2="64.973"/>
                        
                <line x1="108.669" x2="98.141" y1="56.78" y2="62.861"/>
                      
                <line class="hi" stroke="#FF0D0D" x1="99.36" x2="104.6245" y1="64.973" y2="61.932500000000005"/>
                <line class="hi" stroke="#FF0D0D" x1="98.141" x2="103.405" y1="62.861" y2="59.820499999999996"/>
            </g>
                  
            <line class="bond" id="mol1bnd10" x1="105.516" x2="95.472" y1="41.127" y2="35.326"/>
                  
            <line class="bond" id="mol1bnd11" x1="135.085" x2="146.341" y1="42.948" y2="39.328"/>
                  
            <line class="bond" id="mol1bnd12" x1="152.219" x2="158.555" y1="41.857" y2="50.568"/>
                  
            <g class="bond" id="mol1bnd13">
                        
                <line x1="152.219" x2="158.555" y1="59.28" y2="50.568"/>
                        
                <line x1="150.247" x2="155.54" y1="57.845" y2="50.568"/>
                      
                <line class="hi" stroke="#3050F8" x1="152.219" x2="155.387" y1="59.28" y2="54.924"/>
                <line class="hi" stroke="#3050F8" x1="150.247" x2="152.89350000000002" y1="57.845" y2="54.2065"/>
            </g>
                  
            <line class="bond" id="mol1bnd14" x1="135.085" x2="146.341" y1="58.188" y2="61.809"/>
                  
            <line class="bond" id="mol1bnd15" x1="158.555" x2="170.543" y1="50.568" y2="50.568"/>
                  
            <line class="bond" id="mol1bnd16" x1="1.038" x2="11.083" y1="1.038" y2="6.838"/>
                  
            <line class="bond" id="mol1bnd17" x1="17.39" x2="27.435" y1="6.838" y2="1.038"/>
                  
            <line class="bond" id="mol1bnd18" x1="14.236" x2="14.236" y1="12.508" y2="23.898"/>
                  
            <line class="bond" id="mol1bnd19" x1="14.236" x2="27.435" y1="23.898" y2="31.518"/>
                  
            <line class="bond" id="mol1bnd20" x1="27.435" x2="27.435" y1="31.518" y2="42.837"/>
                  
            <line class="bond" id="mol1bnd21" x1="30.71" x2="40.633" y1="48.649" y2="54.378"/>
                  
            <line class="bond" id="mol1bnd22" x1="40.633" x2="40.633" y1="54.378" y2="69.618"/>
                  
            <g class="bond" id="mol1bnd23">
                        
                <line x1="53.841" x2="40.633" y1="77.238" y2="69.618"/>
                        
                <line x1="51.402" x2="40.633" y1="78.647" y2="72.433"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd24" x1="53.841" x2="53.841" y1="77.238" y2="92.478"/>
                  
            <g class="bond" id="mol1bnd25">
                        
                <line x1="40.633" x2="53.841" y1="100.098" y2="92.478"/>
                        
                <line x1="40.633" x2="51.402" y1="97.283" y2="91.07"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd26" x1="40.633" x2="27.425" y1="100.098" y2="92.478"/>
                  
            <g class="bond" id="mol1bnd27">
                        
                <line x1="27.425" x2="27.425" y1="77.238" y2="92.478"/>
                        
                <line x1="29.863" x2="29.863" y1="78.647" y2="91.07"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd28" x1="40.633" x2="27.425" y1="69.618" y2="77.238"/>
                  
            <line class="bond" id="mol1bnd29" x1="40.633" x2="53.831" y1="54.378" y2="46.758"/>
                  
            <g class="bond" id="mol1bnd30">
                        
                <line x1="53.826" x2="53.831" y1="31.51" y2="46.758"/>
                        
                <line x1="56.265" x2="56.269" y1="32.917" y2="45.351"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd31" x1="53.826" x2="67.024" y1="31.51" y2="23.89"/>
                  
            <g class="bond" id="mol1bnd32">
                        
                <line x1="80.228" x2="67.024" y1="31.518" y2="23.89"/>
                        
                <line x1="77.79" x2="67.024" y1="32.926" y2="26.706"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd33" x1="80.228" x2="80.232" y1="31.518" y2="46.767"/>
                  
            <g class="bond" id="mol1bnd34">
                        
                <line x1="67.034" x2="80.232" y1="54.387" y2="46.767"/>
                        
                <line x1="67.035" x2="77.794" y1="51.571" y2="45.359"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd35" x1="53.831" x2="67.034" y1="46.758" y2="54.387"/>
                  
            <path class="atom" d="M123.818 68.258h-.72l-2.62 -4.066h-.029q.012 .238 .029 .595q.024 .357 .024 .732v2.739h-.565v-4.9h.714l2.608 4.055h.029q-.006 -.108 -.018 -.328q-.011 -.22 -.023 -.476q-.006 -.262 -.006 -.482v-2.769h.577v4.9z" id="mol1atm2" stroke="none"/>
                  
            <path class="atom" d="M124.137 20.085q-.0 .756 -.256 1.328q-.256 .565 -.756 .881q-.5 .315 -1.245 .315q-.756 .0 -1.262 -.315q-.506 -.316 -.756 -.887q-.244 -.572 -.244 -1.334q.0 -.75 .244 -1.309q.25 -.566 .756 -.881q.506 -.316 1.274 -.316q.733 .0 1.233 .316q.5 .309 .756 .875q.256 .565 .256 1.327zM120.273 20.085q.0 .923 .387 1.459q.393 .53 1.22 .53q.84 -.0 1.221 -.53q.387 -.536 .387 -1.459q-.0 -.928 -.387 -1.452q-.381 -.524 -1.209 -.524q-.833 -.0 -1.226 .524q-.393 .524 -.393 1.452z" fill="#FF0D0D" id="mol1atm6" stroke="none"/>
                  
            <path class="atom" d="M110.61 45.398h-.72l-2.62 -4.066h-.029q.012 .238 .029 .595q.024 .357 .024 .732v2.739h-.565v-4.9h.714l2.608 4.055h.029q-.006 -.108 -.018 -.328q-.011 -.22 -.023 -.476q-.006 -.262 -.006 -.482v-2.769h.577v4.9z" id="mol1atm7" stroke="none"/>
                  
            <path class="atom" d="M97.732 65.807q-.0 .756 -.256 1.328q-.256 .565 -.756 .881q-.5 .315 -1.245 .315q-.756 .0 -1.262 -.315q-.506 -.316 -.756 -.887q-.244 -.572 -.244 -1.334q.0 -.75 .244 -1.309q.25 -.566 .756 -.881q.506 -.316 1.274 -.316q.733 .0 1.233 .316q.5 .309 .756 .875q.256 .565 .256 1.327zM93.868 65.807q.0 .923 .387 1.459q.393 .53 1.22 .53q.84 -.0 1.221 -.53q.387 -.536 .387 -1.459q-.0 -.928 -.387 -1.452q-.381 -.524 -1.209 -.524q-.833 -.0 -1.226 .524q-.393 .524 -.393 1.452z" fill="#FF0D0D" id="mol1atm9" stroke="none"/>
                  
            <g class="atom" id="mol1atm11">
                        
                <path d="M151.555 40.724h-.72l-2.62 -4.066h-.03q.012 .238 .03 .596q.024 .357 .024 .732v2.738h-.565v-4.899h.714l2.607 4.054h.03q-.006 -.107 -.018 -.327q-.012 -.221 -.024 -.477q-.006 -.262 -.006 -.482v-2.768h.578v4.899z" stroke="none"/>
                        
                <path d="M151.418 35.263h-.619v-2.286h-2.512v2.286h-.613v-4.899h.613v2.071h2.512v-2.071h.619v4.899z" stroke="none"/>
                      
            </g>
                  
            <path class="atom" d="M151.555 65.311h-.72l-2.62 -4.066h-.03q.012 .239 .03 .596q.024 .357 .024 .732v2.738h-.565v-4.899h.714l2.607 4.054h.03q-.006 -.107 -.018 -.327q-.012 -.221 -.024 -.477q-.006 -.261 -.006 -.482v-2.768h.578v4.899z" id="mol1atm13" stroke="none"/>
                  
            <path class="atom" d="M174.289 48.592q-.786 -.0 -1.238 .53q-.453 .523 -.453 1.446q.0 .911 .417 1.447q.423 .53 1.268 .53q.322 -.0 .607 -.054q.292 -.06 .566 -.143v.536q-.274 .101 -.566 .149q-.291 .053 -.696 .053q-.744 .0 -1.25 -.309q-.5 -.31 -.75 -.875q-.25 -.572 -.25 -1.34q-.0 -.744 .267 -1.309q.274 -.566 .804 -.882q.53 -.321 1.28 -.321q.78 -.0 1.351 .286l-.244 .524q-.226 -.102 -.506 -.185q-.273 -.083 -.607 -.083zM177.046 53.015h-.601v-5.215h.601v5.215z" fill="#1FF01F" id="mol1atm14" stroke="none"/>
                  
            <path class="atom" d="M16.177 11.108h-.72l-2.62 -4.066h-.029q.012 .238 .029 .595q.024 .357 .024 .732v2.739h-.565v-4.9h.714l2.608 4.055h.029q-.006 -.108 -.018 -.328q-.011 -.22 -.023 -.476q-.006 -.262 -.006 -.482v-2.769h.577v4.9z" id="mol1atm16" stroke="none"/>
                  
            <path class="atom" d="M29.694 46.755q-.0 .756 -.256 1.328q-.256 .565 -.756 .881q-.5 .315 -1.244 .315q-.756 .0 -1.262 -.315q-.506 -.316 -.757 -.887q-.244 -.572 -.244 -1.334q.0 -.75 .244 -1.309q.251 -.566 .757 -.881q.506 -.316 1.274 -.316q.732 .0 1.232 .316q.5 .309 .756 .875q.256 .565 .256 1.327zM25.83 46.755q.0 .923 .387 1.459q.393 .53 1.221 .53q.839 -.0 1.22 -.53q.387 -.536 .387 -1.459q-.0 -.928 -.387 -1.452q-.381 -.524 -1.208 -.524q-.834 -.0 -1.227 .524q-.393 .524 -.393 1.452z" fill="#FF0D0D" id="mol1atm20" stroke="none"/>
                
            <line class="hi" id="mol1bnd1" stroke="#3050F8" x1="121.877" x2="121.877" y1="69.658" y2="75.35300000000001"/>
            <line class="hi" id="mol1bnd2" stroke="#3050F8" x1="125.031" x2="130.058" y1="63.989" y2="61.088499999999996"/>
            <line class="hi" id="mol1bnd6" stroke="#3050F8" x1="111.823" x2="116.85" y1="41.129" y2="38.2285"/>
            <line class="hi" id="mol1bnd7" stroke="#3050F8" x1="108.669" x2="108.669" y1="46.798" y2="52.493"/>
            <line class="hi" id="mol1bnd8" stroke="#3050F8" x1="118.724" x2="113.6965" y1="63.989" y2="61.088499999999996"/>
            <line class="hi" id="mol1bnd10" stroke="#3050F8" x1="105.516" x2="100.494" y1="41.127" y2="38.2265"/>
            <line class="hi" id="mol1bnd11" stroke="#3050F8" x1="146.341" x2="140.71300000000002" y1="39.328" y2="41.138000000000005"/>
            <line class="hi" id="mol1bnd11" stroke="#3050F8" x1="146.341" x2="140.71300000000002" y1="39.328" y2="41.138000000000005"/>
            <line class="hi" id="mol1bnd12" stroke="#3050F8" x1="152.219" x2="155.387" y1="41.857" y2="46.2125"/>
            <line class="hi" id="mol1bnd12" stroke="#3050F8" x1="152.219" x2="155.387" y1="41.857" y2="46.2125"/>
            <line class="hi" id="mol1bnd14" stroke="#3050F8" x1="146.341" x2="140.71300000000002" y1="61.809" y2="59.9985"/>
            <line class="hi" id="mol1bnd15" stroke="#1FF01F" x1="170.543" x2="164.549" y1="50.568" y2="50.568"/>
            <line class="hi" id="mol1bnd16" stroke="#3050F8" x1="11.083" x2="6.0605" y1="6.838" y2="3.938"/>
            <line class="hi" id="mol1bnd17" stroke="#3050F8" x1="17.39" x2="22.4125" y1="6.838" y2="3.938"/>
            <line class="hi" id="mol1bnd18" stroke="#3050F8" x1="14.236" x2="14.236" y1="12.508" y2="18.203"/>
            <line class="hi" id="mol1bnd20" stroke="#FF0D0D" x1="27.435" x2="27.435" y1="42.837" y2="37.1775"/>
            <line class="hi" id="mol1bnd21" stroke="#FF0D0D" x1="30.71" x2="35.6715" y1="48.649" y2="51.5135"/>
        </g>
          
    </g>
    
</svg>
","Subjective Effects":null,"Therapeutic Uses":"Antiemetics; Histamine H1 Antagonists","Title":"Dimenhydrinate","UNII":"JB937PER5C","Wikidata":"Q420439","Wikipedia":"Dimenhydrinate","XLogP":null,"pH":"SATURATED SOLN HAS PH BETWEEN 6.8 \u0026 7.3"}